journal
MENU ▼
Read by QxMD icon Read
search

Surgical Oncology Clinics of North America

journal
https://www.readbyqxmd.com/read/27889042/preface
#1
EDITORIAL
Cathy Eng
No abstract text is available yet for this article.
January 2017: Surgical Oncology Clinics of North America
https://www.readbyqxmd.com/read/27889041/anal-cancer-2016
#2
EDITORIAL
Nicholas J Petrelli
No abstract text is available yet for this article.
January 2017: Surgical Oncology Clinics of North America
https://www.readbyqxmd.com/read/27889040/evolution-and-management-of-treatment-related-toxicity-in-anal-cancer
#3
REVIEW
Ethan B Ludmir, Lisa A Kachnic, Brian G Czito
Over the past several decades, clinical trials have demonstrated improved disease-related outcomes in the definitive treatment of anal cancer. Although treatment with radiation and concurrent chemotherapy results in high rates of cure, significant acute and late toxicities are seen. This review focuses on the evolution of treatment-related toxicity for anal cancer. Management of these adverse effects is reviewed, as are future directions in anal cancer treatment and their impact on toxicity.
January 2017: Surgical Oncology Clinics of North America
https://www.readbyqxmd.com/read/27889039/epidemiology-of-anal-canal-cancer
#4
REVIEW
Valerie M Nelson, Al B Benson
Anal cancer is a rare malignancy, although its incidence has been increasingly in recent decades. This article discusses risk factors for anal cancer and how these risk factors affect the changing demographics of this disease.
January 2017: Surgical Oncology Clinics of North America
https://www.readbyqxmd.com/read/27889038/treatment-of-the-primary-tumor-in-anal-canal-cancers
#5
REVIEW
Rob Glynne-Jones, Sheela Rao
Radical concurrent chemoradiotherapy with 5-fluorouracil and mitomycin C (MMC) remains the standard of care for squamous cell carcinoma of the anus. Phase III trials over 2 decades have used combined radiation doses of 50 to 60 Gy with concurrent fluoropyrimidines, MMC, or cisplatin in various doses and schedules. Modern radiotherapy techniques allow the production of highly conformal plans, decreasing radiation doses to the organs at risk and ensuring a shorter overall treatment time without the need for treatment breaks...
January 2017: Surgical Oncology Clinics of North America
https://www.readbyqxmd.com/read/27889037/pathology-of-anal-cancer
#6
REVIEW
Paulo M Hoff, Renata Coudry, Camila Motta Venchiarutti Moniz
Anal canal cancer is rather an uncommon disease but its incidence is increasing. Squamous cell carcinoma (SCC) is the most frequent primary anal neoplasm and can encompass a variety of morphologies. HPV infection has a key role in precancerous lesions and cancer development by the production of E6 and E7 oncoproteins. Anal squamous precancerous lesions are now classified according to the same criteria and terminology as their cervical counterparts. The p16 expression by immunohistochemistry is a surrogate marker for human papilloma virus (HPV)...
January 2017: Surgical Oncology Clinics of North America
https://www.readbyqxmd.com/read/27889036/diagnosis-and-diagnostic-imaging-of-anal-canal-cancer
#7
REVIEW
Kristen K Ciombor, Randy D Ernst, Gina Brown
Anal canal cancer is an uncommon malignancy but one that is often curable with optimal therapy. Owing to its unique location, histology, risk factors, and usual presentation, a careful diagnostic approach is warranted. This approach includes an excellent history and physical examination, including digital rectal examination, laboratory data, and comprehensive imaging. Anal cancer staging and formulation of a treatment plan depends on accurate imaging data. Modern radiographic techniques have improved staging quality and accuracy, and a thorough knowledge of anal anatomy is paramount to the optimal multidisciplinary treatment of this disease...
January 2017: Surgical Oncology Clinics of North America
https://www.readbyqxmd.com/read/27889035/anal-dysplasia
#8
REVIEW
Craig A Messick, Miguel A Rodriguez-Bigas
Anal dysplasia is a cytopathology term describing specific squamous cell morphology and represents a varying degree of benign changes. Often a source of confusion, the current iteration includes two types, low-grade and high-grade, and carries significant clinical implications. This article updates readers on the current definition of anal dysplasia, describes its incidence and prevalence, defines high-risk populations, and highlights diagnostics, treatment, and long-term management strategies for patients with anal dysplasia...
January 2017: Surgical Oncology Clinics of North America
https://www.readbyqxmd.com/read/27889034/human-immunodeficiency-virus-aids-human-papillomavirus-and-anal-cancer
#9
REVIEW
Chia-Ching J Wang, Joseph Sparano, Joel M Palefsky
Anal cancer is an increasingly common non-AIDS-defining cancer among individuals infected with the human immunodeficiency virus (HIV). It is associated with human papillomavirus (HPV). HPV16 is the most common genotype detected in anal cancers. The HPV types detected in anal cancer are included in the 9-valent vaccine. HPV vaccines have demonstrated efficacy in reducing anal precancerous lesions in HIV-infected individuals. Standard treatment has been fluorouracil and mitomycin (or cisplatin) plus radiation...
January 2017: Surgical Oncology Clinics of North America
https://www.readbyqxmd.com/read/27889033/uncommon-anal-neoplasms
#10
REVIEW
Amitesh C Roy, David Wattchow, David Astill, Simron Singh, Susan Pendlebury, Kirsten Gormly, Eva Segelov
Uncommon neoplasms of the anal canal are associated with significant diagnostic dilemma in clinical practice and a high index of suspicion and pathologic expertise is needed. The incidence is likely to increase, particularly of small, incidental lesions found because of use of more frequent colonoscopy and high-definition MRI. Generally treatment follows that of the same histologic subtype in other anatomic location. Surgical intervention is the cornerstone for cure in early/localized disease; however, removal of the anal canal is associated with significant morbidities and quality of life issues...
January 2017: Surgical Oncology Clinics of North America
https://www.readbyqxmd.com/read/27889032/metastatic-anal-cancer-and-novel-agents
#11
REVIEW
Van Morris, Cathy Eng
Squamous cell carcinoma of the anal canal (SCCA) represents an orphan disease. Although prior infection with human papilloma virus is associated with the development of SCCA, knowledge of this relationship has proven ineffective in identifying therapeutic agents that have activity in the management of metastatic SCCA. Combination chemotherapy with traditional cytotoxic agents has demonstrated efficacy in multiple small series. However, immune checkpoint blockade agents have demonstrated efficacy for patients with refractory metastatic SCCA; these agents hold promise in the horizon for patients with metastatic SCCA...
January 2017: Surgical Oncology Clinics of North America
https://www.readbyqxmd.com/read/27889031/surveillance-of-anal-canal-cancers
#12
REVIEW
Richard Adams
Anal squamous cell cancer is most frequently a locoregional disease that is amenable to curative therapy in a majority of fit patients. Complete response rates after chemoradiotherapy (CRT) are good, with up to 75% of patients with no evidence of relapse on surveillance. Relapse is most frequently locoregional and is often amendable to salvage surgery with curative intent. Effective surveillance attempts to improve outcomes by identifying recurrent or persistent disease early, managing both acute and late toxicities, and offering reassurance to patients...
January 2017: Surgical Oncology Clinics of North America
https://www.readbyqxmd.com/read/27889030/locally-recurrent-disease-related-to-anal-canal-cancers
#13
REVIEW
Tarik Sammour, Miguel A Rodriguez-Bigas, John M Skibber
Surgery for anal cancer is usually reserved for patients with persistent disease or local recurrence after definitive chemoradiation therapy. Patients with local recurrence should be re-evaluated for evidence of metastatic disease using positron emission tomography-computed tomography, and the local anatomy should be delineated with MRI. Eligible patients should undergo tailored surgery with the aim of achieving an R0 resection. Management is best undertaken within a specialized multidisciplinary setting. Careful patient selection and shared decision making are paramount for achieving acceptable patient-centered outcomes...
January 2017: Surgical Oncology Clinics of North America
https://www.readbyqxmd.com/read/27889029/patient-perspective-and-personal-journey-of-treating-a-rare-cancer
#14
REVIEW
Michele Longabaugh
I was diagnosed with rare anal cancer. As overwhelming as the diagnosis was, it was complicated by limited treatment infrastructure and clinical research, side-effect management, and lack of awareness and support organizations. Anal cancer encompasses so much more than receiving prescribed treatment and focusing on recovery. It requires patients to become experts on their disease, its treatment, and side effects. Even more challenging is finding support and advocacy. My experience has been difficult, complex, and arduous...
January 2017: Surgical Oncology Clinics of North America
https://www.readbyqxmd.com/read/27591505/preface
#15
EDITORIAL
Chandrajit P Raut
No abstract text is available yet for this article.
October 2016: Surgical Oncology Clinics of North America
https://www.readbyqxmd.com/read/27591504/sarcomas-2016
#16
EDITORIAL
Nicholas J Petrelli
No abstract text is available yet for this article.
October 2016: Surgical Oncology Clinics of North America
https://www.readbyqxmd.com/read/27591503/chemotherapy-does-neoadjuvant-or-adjuvant-therapy-improve-outcomes
#17
REVIEW
Robert J Canter
Since preoperative chemotherapy has been clearly shown to improve outcomes for patients with Ewing sarcoma, rhabdomyosarcoma, and osteosarcoma, practitioners have attempted to extend the use of adjuvant/neoadjuvant chemotherapy to other types of adult soft tissue sarcoma. Given the high risk of distant recurrence and disease-specific death for patients with soft tissue sarcoma tumors larger than 10 cm, these patients should be considered candidates for neoadjuvant chemotherapy as well as investigational therapies...
October 2016: Surgical Oncology Clinics of North America
https://www.readbyqxmd.com/read/27591502/radiation-therapy-for-soft-tissue-sarcoma-indications-and-controversies-for-neoadjuvant-therapy-adjuvant-therapy-intraoperative-radiation-therapy-and-brachytherapy
#18
REVIEW
Nicole A Larrier, Brian G Czito, David G Kirsch
Soft tissue sarcomas are rare mesenchymal cancers that pose a treatment challenge. Although small superficial soft tissue sarcomas can be managed by surgery alone, adjuvant radiotherapy in addition to limb-sparing surgery substantially increases local control of extremity sarcomas. Compared with postoperative radiotherapy, preoperative radiotherapy doubles the risk of a wound complication, but decreases the risk for late effects, which are generally irreversible. For retroperitoneal sarcomas, intraoperative radiotherapy can be used to safely escalate the radiation dose to the tumor bed...
October 2016: Surgical Oncology Clinics of North America
https://www.readbyqxmd.com/read/27591501/dermatofibrosarcoma-protuberans-wide-local-excision-versus-mohs-micrographic-surgery
#19
REVIEW
John T Mullen
Dermatofibrosarcoma protuberans (DFSP) is a rare dermal soft tissue sarcoma characterized by a typically indolent clinical course. The greatest clinical challenge in management of DFSP is achieving local control. There is vigorous debate in the literature as to the optimal surgical approach to these tumors. The choice between wide local excision and Mohs micrographic surgery for DFSP should be governed by the attainment of three goals: (1) to completely excise the tumor with negative margins, tantamount to cure; (2) to preserve function, optimize cosmesis, and minimize morbidity of resection; and (3) to minimize cost and inconvenience to the patient and the health care system at large...
October 2016: Surgical Oncology Clinics of North America
https://www.readbyqxmd.com/read/27591500/desmoid-type-fibromatosis-evolving-treatment-standards
#20
REVIEW
Marco Fiore, Andrea MacNeill, Alessandro Gronchi, Chiara Colombo
Desmoid-type fibromatosis is a rare nonmetastasizing neoplasm with variable behavior. Recent discoveries into the biology of this disease hold promise for identifying prognostic and predictive features and novel therapeutic targets. Surgery has been the historical standard of care but carries considerable drawbacks in terms of high local recurrence rates and poor functional outcomes. Improved understanding of the natural history of desmoid-type fibromatosis has resulted in a paradigm shift toward nonoperative management...
October 2016: Surgical Oncology Clinics of North America
journal
journal
31108
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"